The chemotherapy-induced myelosuppression treatment market is expected to reach a valuation of US$ 9.78 Billion by 2028, rising at a CAGR of 3.3% from its current value of US$ 8.06 Billion in 2022. A new study by FMI reveals that the chemotherapy-induced myelosuppression treatment market is expected to grow at a subdued 3% y-o-y in 2019. Valued …